Background The present review is part of the ESCMID Study Group for Infections in
Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and …

Background Biological therapy is currently widely used to treat IBD. Infliximab, adalimumab
and golimumab are currently licensed anti‐TNF therapies. Biosimilar anti‐TNF monoclonal …

The introduction and broad use of new immunosuppressive agents, including biologic
agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease …

6.1. Background The incidence of tuberculosis (TB) is a concern at the start of the third
millennium, particularly with the increase of multiresistant (MDR-TB) and extended resistant …

Guidelines for clinical practice are aimed to indicate preferred approaches to medical
problems as established by scientifically valid research. Double-blind placebo controlled …

The clinical introduction of tumour necrosis factor (TNF) inhibitors has deeply changed the
treatment of inflammatory bowel diseases (IBD). It has demonstrated impressive efficacy as …

Objectives The aim of this prospective study was to examine the safety of anti-tumour
necrosis factor (TNF) therapy in patients with rheumatic disease and hepatitis B virus (HBV) …

Objective To assess the safety of anti–tumor necrosis factor α (anti‐TNFα) therapy on the
course of hepatitis B virus (HBV) infection in carriers of antibodies to hepatitis B core antigen …

Ulcerative colitis (UC) and Crohn disease (CD), collectively referred to as inflammatory
bowel disease (IBD), are chronic inflammatory disorders that can affect the gastrointestinal …

Hepatitis B virus (HBV) infection can result in a spectrum of outcomes from immune-
mediated control to disease progression, cirrhosis, and liver cancer. The host molecular …